From bb32e1968c24e698c33a4404f7fab022f6aa57ea Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 10 May 2026 04:15:09 +0000 Subject: [PATCH] auto-fix: strip 4 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- .../2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md | 2 +- inbox/queue/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md | 2 +- .../2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md | 2 +- ...26-04-18-trump-executive-order-psychedelics-mental-health.md | 2 +- 4 files changed, 4 insertions(+), 4 deletions(-) diff --git a/inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md b/inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md index 35c55632e..d5621f70e 100644 --- a/inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md +++ b/inbox/queue/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md @@ -60,7 +60,7 @@ intake_tier: research-task **KB connections:** - [[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]] — analogous pattern: clinical benefit in trials doesn't translate to regulatory success if methodology is flawed -- [[healthcare AI regulation needs blank-sheet redesign]] — related but distinct: here the issue is trial methodology for a drug, not regulation of AI +- healthcare AI regulation needs blank-sheet redesign — related but distinct: here the issue is trial methodology for a drug, not regulation of AI - Contrast with Compass Pathways archives (COMP005, COMP006) — psilocybin passed; MDMA failed; the methodology difference (active comparator vs. inert placebo) explains the divergence **Extraction hints:** diff --git a/inbox/queue/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md b/inbox/queue/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md index eef58b0b4..671dfc0aa 100644 --- a/inbox/queue/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md +++ b/inbox/queue/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md @@ -64,7 +64,7 @@ intake_tier: research-task **KB connections:** - [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] — veterans' mental health is a specific, politically salient subset of the broader mental health supply gap -- [[healthcare AI regulation needs blank-sheet redesign]] — ibogaine raises a different regulatory question: how do you conduct blinded trials for a drug with such profound psychoactive effects? +- healthcare AI regulation needs blank-sheet redesign — ibogaine raises a different regulatory question: how do you conduct blinded trials for a drug with such profound psychoactive effects? - Connects to the MDMA-AT CRL archive: functional unblinding problem exists for ibogaine too; how will Phase 3 trials be designed? **Extraction hints:** diff --git a/inbox/queue/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md b/inbox/queue/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md index a7fdd2c02..d5632e2d0 100644 --- a/inbox/queue/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md +++ b/inbox/queue/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md @@ -56,7 +56,7 @@ intake_tier: research-task **KB connections:** - DIRECTLY CHALLENGES: [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]] — this claim is now temporally incorrect for 2024 - COMPLICATES: Belief 1 grounding ("compounding failure") — the acute acute dimension is improving -- CONNECTS TO: [[Big Food companies engineer addictive products by hacking evolutionary reward pathways]] — food-driven chronic disease threat remains even as drug deaths improve +- CONNECTS TO: Big Food companies engineer addictive products by hacking evolutionary reward pathways — food-driven chronic disease threat remains even as drug deaths improve - CONNECTS TO: IHME 2050 forecast (structural metabolic threat persists) **Extraction hints:** diff --git a/inbox/queue/2026-04-18-trump-executive-order-psychedelics-mental-health.md b/inbox/queue/2026-04-18-trump-executive-order-psychedelics-mental-health.md index bcfc7ebc8..5200fd959 100644 --- a/inbox/queue/2026-04-18-trump-executive-order-psychedelics-mental-health.md +++ b/inbox/queue/2026-04-18-trump-executive-order-psychedelics-mental-health.md @@ -66,7 +66,7 @@ intake_tier: research-task **What I expected but didn't find:** Any reference to MDMA-AT specifically. Methylone (TSND-201, Transcend Therapeutics) received a voucher — this is an MDMA-like compound but a distinct chemical entity, addressing the MDMA regulatory failure by pursuing a related molecule with cleaner trial design. **KB connections:** -- [[healthcare AI regulation needs blank-sheet redesign]] — by contrast, this EO uses EXISTING regulatory frameworks (Right to Try, priority review) rather than new ones +- healthcare AI regulation needs blank-sheet redesign — by contrast, this EO uses EXISTING regulatory frameworks (Right to Try, priority review) rather than new ones - [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] — if psilocybin is approved, it creates a new category for the most treatment-resistant patients; but access will be clinic-based (not scalable) - Belief 3: EO represents regulatory system responding to clinical evidence + political pressure — BUT: it's using expedited tools that may create safety risks if approval happens before adequate real-world evidence accumulates